Xenon Pharmaceuticals (XENE) Change in Accured Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 52.39% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 23.27% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 35.4% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.8 million, down from $2.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for XENE reached as high as $9.2 million in Q2 2024 and fell as low as -$5.8 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged $1.4 million across 5 years, with a median of $2.1 million in 2022.
• Across the five-year window, Change in Accured Expenses sank 744.78% in 2024 and surged 439.6% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $6.0 million in 2022, then tumbled by 61.76% to $2.3 million in 2023, then surged by 168.75% to $6.2 million in 2024, then plunged by 61.95% to $2.4 million in 2025, then plunged by 176.54% to -$1.8 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.8 million in Q1 2026, $2.4 million in Q4 2025, and $6.1 million in Q3 2025.